WST

• Second-quarter 2026 net sales were $872.3 million, up 13.8% reported and 12.7% organic year-over-year.
• Operating cash flow was $213.9 million, capital expenditures were $85.9 million, and free cash flow was $128.0 million.
• Full-year 2026 net sales guidance raised to $3.345-$3.380 billion; adjusted-diluted EPS guidance raised to $8.85-$9.05.
• Third-quarter 2026 net sales guidance introduced at $820-$835 million; adjusted-diluted EPS guidance of $2.14-$2.24.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• West Pharmaceutical Services, Inc. and Daikyo Seiko, Ltd. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements effective July 14, 2026.
• The Crosslicense Agreement covers sharing know-how and joint development of pharmaceutical packaging and delivery products, with West's license from Daikyo exclusive outside Japan and Daikyo's license from West non-exclusive.
• One Distributorship Agreement makes West the exclusive distributor of Daikyo products outside Japan; the other makes Daikyo a non-exclusive distributor of West products in Japan.
• Each agreement has a 10-year term and may be terminated under certain conditions, including mutual consent or change in control.

1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits

• Michel Lagarde will become President and CEO and join the Board on August 31, 2026, succeeding Eric M. Green, who retires that day.
• Lagarde's employment agreement provides a $1,175,000 base salary, a target annual incentive of 125% of salary, and 2026 LTI awards with a total grant value of $8,611,111.
• He will receive one-time inducement equity awards with a maximum aggregate grant value of $10,000,000, including a sign-on grant of $6,875,000 and matching grants tied to his personal stock purchases.
• Lagarde previously served as Executive Vice President and COO at Thermo Fisher Scientific and has been a Vertex Pharmaceuticals board member since 2023.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• On May 7, 2026, West Pharmaceutical Services determined it experienced a material cybersecurity attack involving data exfiltration and system encryption.
• The company engaged Palo Alto Networks' Unit 42 to support investigation, containment, and recovery efforts.
• The incident has temporarily disrupted global business operations; core enterprise systems are restored, and shipping, receiving, and manufacturing have restarted at some sites, with full restoration timeline not yet finalized.
• The material impact on financial condition and results of operations has not been determined as of the filing date.

1.05 Material Cybersecurity Incidents · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• West Pharmaceutical Services, Inc. held its 2026 Annual Meeting of Shareholders virtually on May 4, 2026.
• The non-binding advisory vote on named executive officer compensation was approved with 60,107,802 votes for and 3,762,206 against.
• The appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 was ratified with 58,509,119 votes for and 7,556,514 against.
• A shareholder proposal for an Independent Board Chair Policy was not approved, with 29,592,488 for and 34,245,125 against.

5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits

• Diluted EPS was $1.92, up 56.1%; adjusted-diluted EPS was $2.13, up 46.9%.
• Operating cash flow was $89.9 million, capital expenditures were $42.7 million, and free cash flow was $47.2 million.
• The company repurchased 1.2 million shares for $297.6 million at an average price of $243.57 per share.
• Full-year 2026 net sales guidance raised to $3.295-$3.350 billion and adjusted-diluted EPS guidance raised to $8.40-$8.75; Q2 2026 net sales guided to $830-$850 million.

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The retirement is effective once a successor is hired, with the transition expected in the second half of 2026.
• The Board is engaging a leading executive recruiting firm to assist with the search for a successor.
• Green has served as President and CEO since April 2015 and became Chair of the Board in May 2022.
• The company reaffirmed its 2026 financial guidance provided in its February 12, 2026 earnings release.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Full-year 2025 net sales were $3.074 billion, up 6.3% (organic growth 4.3%); diluted EPS was $6.79, up 1.5%; adjusted-diluted EPS was $7.29, up 8.0%.
• Proprietary Products segment Q4 net sales grew 7.8% to $661.8 million, with High-Value Product Components up 20.3% (organic 15.1%) driven by Westar and Envision products.
• Full-year 2026 guidance: net sales $3.215-$3.275 billion (reported growth 4.6%-6.5%, organic ~5%-7%), adjusted-diluted EPS $7.85-$8.20 (growth 7.7%-12.5%), capex $250-$275 million.
• First-quarter 2026 guidance: net sales $770-$790 million (reported growth 10.3%-13.2%, organic 4.6%-7.4%), adjusted-diluted EPS $1.65-$1.70 (up 13.0%-16.4%).

2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits